Biomarkers for Neuroprotective Drug Evaluation

A key need to improve the translation of preclinical neuroprotective effects into successful mechanism-based clinical trials is the identification of measurable biomarkers that allow the pathophysiology and drug effects thereon to be determined. Three examples of promising CNS injury biomarkers are the LP-related isoprostanes30 and neuroprostanes,31 calpain and caspase-3-mediated degradation products of the cytoskeletal protein a-spectrin,32 and the astrocytic injury marker S100p.33'34 The validation of these for the monitoring of postischemic or posttraumatic injury is ongoing in multiple centers and should lead to a quantifiable means for the more efficient clinical evaluation of neuroprotective pharmacotherapies with regard to neuroprotective efficacy, dose-response, therapeutic window, and optimal dosing regimen determinations.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment